Bob
Senior Member
- Messages
- 16,455
- Location
- England (south coast)
Experimental research seeking a way to treat autoimmune disease without disrupting normal immune activity.
This research engineers T cells to target and eliminate specific B cells in order to treat autoimmune disease.
The immune system can be trained to attack itself to reverse a devastating autoimmune disease, in animal studies.
BBC News.
1 July 2016
http://www.bbc.co.uk/news/health-36662305
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
Ellebrecht CT, Bhoj VG, Nace A, Jung Choi E, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, Milone MC, Payne AS.
Science
Published Online 30 Jun 2016
http://science.sciencemag.org/content/early/2016/06/29/science.aaf6756
This research engineers T cells to target and eliminate specific B cells in order to treat autoimmune disease.
The immune system can be trained to attack itself to reverse a devastating autoimmune disease, in animal studies.
BBC News.
1 July 2016
http://www.bbc.co.uk/news/health-36662305
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
Ellebrecht CT, Bhoj VG, Nace A, Jung Choi E, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, Milone MC, Payne AS.
Science
Published Online 30 Jun 2016
http://science.sciencemag.org/content/early/2016/06/29/science.aaf6756
Abstract
Ideally, therapy for autoimmune diseases should eliminate pathogenic autoimmune cells while sparing protective immunity, but feasible strategies for such an approach have been elusive. Here, we show that in the antibody-mediated autoimmune disease pemphigus vulgaris (PV), autoantigen-based chimeric immunoreceptors can direct T cells to kill autoreactive B lymphocytes through the specificity of the B cell receptor (BCR). We engineered human T cells to express a chimeric autoantibody receptor (CAAR), consisting of the PV autoantigen, desmoglein (Dsg) 3, fused to CD137-CD3ζ signaling domains. Dsg3 CAAR-T cells exhibit specific cytotoxicity against cells expressing anti-Dsg3 BCRs in vitro and expand, persist, and specifically eliminate Dsg3-specific B cells in vivo. CAAR-T cells may provide an effective and universal strategy for specific targeting of autoreactive B cells in antibody-mediated autoimmune disease.